Company Quick10K Filing
Vaparia
Price-0.00 EPS-0
Shares76 P/E0
MCap-0 P/FCF0
Net Debt-0 EBIT-0
TEV-0 TEV/EBIT0
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-06-30 Filed 2020-08-14
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-04-10
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-06
10-Q 2019-03-31 Filed 2019-05-13
10-K 2018-12-31 Filed 2019-03-29
10-Q 2018-09-30 Filed 2018-10-31
10-Q 2018-06-30 Filed 2018-08-07
10-Q 2018-03-31 Filed 2018-05-01
10-K 2017-12-31 Filed 2018-03-29
10-Q 2017-09-30 Filed 2017-11-09
10-Q 2017-06-30 Filed 2017-08-11
10-Q 2017-03-31 Filed 2017-05-08
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-09
10-Q 2016-06-30 Filed 2016-08-11
10-Q 2016-03-31 Filed 2016-05-10
10-K 2015-12-31 Filed 2016-04-08
10-Q 2015-09-30 Filed 2015-10-30
10-Q 2015-06-30 Filed 2015-08-13
10-Q 2015-03-31 Filed 2015-05-06
10-K 2014-12-31 Filed 2015-04-14
10-Q 2014-09-30 Filed 2014-11-13
10-Q 2014-06-30 Filed 2014-08-12
10-Q 2014-03-31 Filed 2014-05-20
10-K 2013-12-31 Filed 2014-04-18
8-K 2020-09-04 Other Events
8-K 2020-08-25 Other Events
8-K 2020-08-01 Officers
8-K 2020-07-24 Enter Agreement, Exhibits
8-K 2020-06-04
8-K 2020-04-27
8-K 2020-01-29
8-K 2019-12-31
8-K 2019-12-18
8-K 2019-08-27

VAPA 10Q Quarterly Report

Part 1 - Financial Information
Item 1. Financial Statements.
Note 1 - Nature of Business and Summary of Basis of Presentation
Note 2 - Going Concern
Note 3 - Stockholders' Equity
Note 4 - Related Party Transactions
Note 5 - Note Payable
Note 6 - Convertible Note
Note 7 - Commitment and Contingencies
Note 8 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
Part II - Other Information
Item 1. Legal Proceedings.
Item 1A. Risk Factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Item 3. Defaults Upon Senior Securities.
Item 4. Mine Safety Disclosures.
Item 5. Other Information.
Item 6. Exhibits.
EX-31.1 ex31-1.htm
EX-31.2 ex31-2.htm
EX-32.1 ex32-1.htm

Vaparia Earnings 2020-06-30

Balance SheetIncome StatementCash Flow

10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

(Mark One)

 

 [X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
For the quarterly period ended June 30, 2020

 

or

 

 [  ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
For the transition period from ___________ to _____________
     
Commission file number 000-55470

 

CQENS Technologies Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   27-1521407

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

5550 Nicollet Avenue, Minneapolis, MN   55419
(Address of principal executive offices)   (Zip Code)

 

(612) 812-2037

(Registrant’s telephone number, including area code)

 

not applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   not applicable   not applicable

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
Non-accelerated filer [X] Smaller reporting company [X]
Emerging growth company [X]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [  ] No [X]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 25,369,113 shares of common stock are issued and outstanding as of August 14, 2020.

 

 

 

 

 

 

TABLE OF CONTENTS

 

 

2

 

 

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION

 

This report includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “aim,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. Forward-looking statements include, but are not limited to, statements about:

 

  our history of losses, lack of revenues and insufficient working capital;
     
  our ability to continue as a going concern;
     
  the possible impact of COVID-19 on our company;
     
  our ability to raise capital to fund our business plan, pay our operating expense and satisfy our obligations;
     
  our limited operating history and lack of developed, proven or launched products;
     
  the lack of operating history of Leap Technology LLC (“Leap Technology”) and the risks it will face as a new business venture;
     
  conflicts of interest facing certain of our officers and directors;
     
  future reliance on third parties to formulate and manufacturer our products;
     
  our future ability to comply with government regulations;
     
  our lack of experience in selling, marketing or distributing products;
     
  our future ability to establish and maintain strategic partnerships;
     
  our possible future dependence on licensing or collaboration agreements;
     
  the inability of Xten Capital Group Inc., formerly Chong Corporation (“Xten”), to protect the intellectual property which is licensed to us, and risks of possible third-party infringement of intellectual property rights;
     
  the lack of a public market for our common stock; and
     
  anti-takeover provisions of Delaware law.

 

You should read thoroughly this report and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements, Part 1. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2019 as filed on April 10, 2020 (the “2019 10-K”) and our other filings with the Securities and Exchange Commission. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. These forward-looking statements speak only as of the date of this report, and you should not rely on these statements without also considering the risks and uncertainties associated with these statements and our business.

 

OTHER PERTINENT INFORMATION

 

Unless specifically set forth to the contrary, when used in this report the terms “CQENS,” “we,” “our,” “us,” and similar terms refers to CQENS Technologies Inc., a Delaware corporation formerly known as VapAria Corporation and, where applicable, VapAria Solutions Inc., a Minnesota corporation (“VapAria Solutions”), a wholly owned subsidiary of CQENS. In 2019 we dissolved VapAria Solutions which had no separate operations, assets or liabilities. In addition, “second quarter 2020” refers to the three months ended June 30, 2020, “second quarter 2019” refers to the three months ended June 30, 2019, “2019” refers to the year ended December 31, 2019, and “2020” refers to the year ending December 31, 2020. The information which appears on our web site at www.cqens.com is not part of this report.

 

All share and per share information appearing in this report gives pro forma effect to the one for seven (1:7) reverse stock split of our outstanding common stock on December 26, 2019.

 

3

 

 

PART 1 – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

CQENS Technologies Inc.

Balance Sheets

 

   June 30, 2020   December 31, 2019 
   (Unaudited)     
ASSETS          
Current Assets          
Cash and cash equivalents  $1,687,887   $1,298 
Prepaid expenses   57,464    1,553 
Total Current Assets   1,745,351    2,851 
Intellectual property, net   320,790    290,346 
TOTAL ASSETS  $2,066,141   $293,197 
LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)          
LIABILITIES          
Current Liabilities          
Accounts payable  $60,857   $10,722 
Credit card payable   508    - 
Accrued expenses   98,137    6,865 
Interest payable   -    48,232 
Note payable   -    50,000 
Convertible note   -    40,000 
Loan from related party   455,544    703,044 
Total Current Liabilities   615,046    858,863 
TOTAL LIABILITIES   615,046    858,863 
STOCKHOLDERS’ EQUITY (DEFICIT)          
Common Stock: $0.0001 par value; 200,000,000 shares authorized: 25,371,908 shares issued and outstanding at June 30, 2020 and 24,837,203 issued and outstanding at December 31, 2019   2,537    2,484 
Additional paid-in capital   4,322,879    1,733,900 
Accumulated deficit   (2,874,321)   (2,302,050)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)   1,451,095    (565,666)
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)  $2,066,141   $293,197 

 

See accompanying notes to unaudited financial statements

 

4

 

 

CQENS Technologies Inc.

Statements of Operations

(Unaudited)

 

   Three months ended June 30,   Six months ended June 30, 
   2020   2019   2020   2019 
Operating Expenses                    
General and administrative  $7,005   $6,936   $116,551   $14,013 
Research and development - related party   139,790    -    270,246    - 
Professional fees   152,476    11,361    181,616    31,018 
Total Operating Expenses   299,271    18,297    568,413    45,031 
Other (Expense)        (1,994)   (3,858)   (4,417)
Net Loss  $(299,271)  $(20,291)  $(572,271)  $(49,448)
                     
Basic and diluted loss per common share   (0.01)   (0.00)   (0.02)   (0.00)
Basic and diluted weighted average shares outstanding   25,196,481    10,758,631    25,105,040    10,758,631 

 

See accompanying notes to unaudited financial statements

 

5

 

 

CQENS Technologies Inc.

Statements of Changes in Stockholders’ Equity (Deficit)

For the three and six months ended June 30, 2020 and 2019

(Unaudited)

 

    Series A                                
    Preferred Stock     Common Stock     Additional              
    Number of shares     $0.0001 Par Value     Number of Shares     $0.0001 Par Value     Paid in Capital     Accumulated Deficit     Total   
Balance, March 31, 2020     0     $       -       25,101,035     $ 2,510     $ 3,010,791     $ (2,575,050 )   $ 438,251  
                                                                
Common stock issued for cash     -       -       248,450       25       1,199,975       -     $ 1,200,000  
                                                         
Common stock issued for consulting services     -       -       22,423       2       112,113       -     $ 112,115  
                                                         
Net Loss     -       -       -       -       -       (299,271 )   $ (299,271 )
                                                         
Balance, June 30, 2020     0     $ -       25,371,908     $ 2,537     $ 4,322,879     $ (2,874,321 )   $ 1,451,095  

 

    Series A                                
    Preferred Stock     Common Stock     Additional              
    Number of shares     $0.0001 Par Value     Number of Shares     $0.0001 Par Value     Paid in Capital     Accumulated Deficit     Total  
Balance, December 31, 2019     0     $ -       24,837,203     $ 2,484     $ 1,733,900     $ (2,302,050 )    $ (565,666 )
                                                                        
Common stock issued for cash     -       -       496,898       50       2,399,950       -     $ 2,400,000  
                                                         
Common stock issued for note payable     -       -       15,384       1       76,916       -     $ 76,917  
                                                         
Common stock issued for consulting services     -       -       22,423       2       112,113       -     $ 112,115  
                                                         
Net Loss     -       -       -       -       -       (572,271 )   $ (572,271 )
                                                         
Balance, June 30, 2020     0     $ -       25,371,908     $ 2,537     $ 4,322,879     $ (2,874,321 )   $ 1,451,095  

 

   Series A                     
   Preferred Stock   Common Stock   Additional         
   Number of shares   $0.0001 Par Value   Number of Shares   $0.0001 Par Value   Paid in Capital   Accumulated Deficit   Total 
Balance, March 31, 2019   500,000   $50    10,758,631   $1,076   $1,622,728   $(2,191,328)  $(567,474)
                                    
Net Loss   -    -    -    -    -    (20,291)  $(20,291)
                                    
Balance, June 30, 2019   500,000   $50    10,758,631   $1,076   $1,622,728   $(2,211,619)  $(587,765)

 

   Series A                     
   Preferred Stock   Common Stock   Additional         
   Number of shares   $0.0001 Par Value   Number of Shares   $0.0001 Par Value   Paid in Capital   Accumulated Deficit   Total 
Balance, December 31, 2018   500,000   $50    10,758,631   $1,076   $1,622,728   $(2,162,171)  $(538,317)
                                    
Net Loss   -    -    -    -    -    (49,448)  $(49,448)
                                    
Balance, June 30, 2019   500,000   $50    10,758,631   $1,076   $1,622,728   $(2,211,619)  $(587,765)

 

See accompanying notes to unaudited financial statements

 

6

 

 

CQENS Technologies Inc.

Statements of Cash Flows

(Unaudited)

 

   Six Months Ended June 30, 
   2020   2019 
         
Cash flows from operating activities          
Net loss  $(572,271)  $(49,448)
Adjustments to reconcile net loss to net cash used in operations:          
Amortization expense   9,472    8,742 
Common stock issued for consulting services   112,115    - 
Changes in operating assets and liabilities:          
Prepaid expenses   (55,911)   (2,400)
Accounts payable   50,135    3,254 
Credit card payable   508    - 
Accrued expenses   91,831    - 
Interest payable   (21,874)   3,967 
Net cash used in operating activities   (385,995)   (35,885)
           
Cash flows from investing activities          
Additions to intellectual property   (39,916)   - 
Net cash flows used in investing activities   (39,916)   - 
           
Cash flows from financing activities          
Proceeds from issuance of common stock   2,400,000    - 
Borrowing on debt with related party   2,500    37,000 
Repayment of related party debt   (250,000)   - 
Repayment of convertible note   (40,000)   - 
Net cash provided by financing activities   2,112,500    37,000 
           
Net change in cash and cash equivalents   1,686,589    1,115 
Cash and cash equivalents, beginning of period   1,298    1,477 
Cash and cash equivalents, end of period  $1,687,887   $2,592 
           
Supplementary Information          
Interest paid  $22,323   $- 
Income taxes paid   -    - 
           
Supplementary disclosure of non-cash activities:          
Common stock issued from conversion of note payable and accrued interest  $76,917   $- 

 

See accompanying notes to unaudited financial statements

 

7

 

 

CQENS Technologies, Inc.

(Formerly VapAria Corporation)

Notes to Unaudited Financial Statements

June 30, 2020

 

NOTE 1 - NATURE OF BUSINESS AND SUMMARY OF BASIS OF PRESENTATION

 

Nature of Business

 

CQENS Technologies, Inc., formerly known as VapAria Corporation (“CQENS”, “us”, “we,” “our” or the “Company”), was incorporated under the laws of the State of Delaware on December 21, 2009 under the name OICco Acquisition IV, Inc.

 

The Company is a technology company with a proprietary method of heating plant-based consumable formulations that produce an aerosol that lead to the effective and efficient inhalation of the plant’s constituents. This is accomplished at a high temperature but without the accompanying constituents of combustion. Our system of heating is a high temperature, non-combustion system. Our Heat-not-Burn Tobacco Product (HTP) system is a patent-pending method of heating plant-based consumables for inhalation that is superior to other methods of ingestion, smoking, vaping, swallowing or via topical application.

 

In the first half of 2020 the effects of the COVID-19 pandemic began to be felt. While the duration and full impact of the pandemic is unknown at this time, we expect that the pandemic will adversely impact the Company in several ways. Our business model is dependent upon our ability to enter into strategic partnerships in the future, including alliances with consumer product companies, to enhance and accelerate the development and commercialization of our proposed products. We will also be dependent upon third party manufacturers to produce our proposed products, as well as third party marketing and distribution companies. We believe that our business opportunities are international in nature and include potential partnerships in the UK, the EU and Asia, including the People’s Republic of China. The worldwide pandemic caused by COVID-19 could cause these opportunities to be delayed or significantly limited in their scope should the pandemic continue and /or be prolonged into 2021. We also need to raise additional working capital to provide sufficient funding to bring our proposed products to market. The adverse impact of COVID-19 on the capital markets will make it more difficult for small, pre-revenue companies such as ours to access capital. We will continue to assess the impact of the COVID-19 pandemic on our company, however, at this time we are unable to predict all possible impacts on our company, our operations and our prospects.

 

The Company has limited operations and, while our executive officers devote a substantial amount of their time to the Company, with limited cash compensation, as of June 30, 2020, had no employees.

 

The Company has a fiscal year end of December 31.

 

Basis of Presentation

 

Basis of Presentation - The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows as of June 30, 2020 have been made.

 

Certain information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and footnotes thereto in the Company’s December 31, 2019 audited financial statements. The results of operations for the period ended June 30, 2020 are not necessarily indicative of the operating results for the full year.

 

Reclassifications – Certain reclassifications may have been made to our prior year’s consolidated financial statements to conform to current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.

 

8

 

 

Recent Accounting Pronouncements – Management has evaluated recently issued accounting pronouncements and does not believe that any of these pronouncements will have significant impact on our financial statements and related disclosures.

 

NOTE 2 – GOING CONCERN

 

The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. Currently, the Company has recurring losses, and although has cash in excess of one million dollars, with renewed research and development efforts and with no source of revenue sufficient to cover its operations costs over the next 12 months, the anticipated expenses and lack of current revenues may not allow it to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company will be dependent upon the raising of additional capital. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

 

NOTE 3 – STOCKHOLDERS’ EQUITY

 

On January 29, 2020 we sold 248,448 shares of our common stock for $1,200,000 to a non-U.S. person in a private transaction in reliance on an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on an exemption provided by Regulation S promulgated thereunder. We did not pay a commission or finder’s fee and are using the proceeds for working capital.

 

On March 6, 2020, the holder of the $50,000 note that was entered into on May 30, 2013 agreed to convert the principal and accrued unpaid interest totaling $76,917 into shares of CQENS’ common stock at $5.00 per share. A total of 15,384 shares were issued as satisfaction of this note. The issuance was exempt from registration under the Securities Act in reliance on an exemption provided by Section 3(a)(9) of such act.

 

On April 13, 2020 we entered into a consulting engagement memorandum with an unrelated third party pursuant to which we engaged this party to identify key Asian resources for our company. As compensation for the services we issued this individual 12,423 shares of our common stock valued at $62,115. The recipient was a non-U.S. person and the issuance was exempt from registration under the Securities Act in reliance on an exemption provided by Regulation S promulgated thereunder.

 

On April 16, 2020 we entered into a consulting engagement memorandum and agreement with an unrelated third party and engaged this individual to provide certain services to us in connection with the further development of certain of our patents. As compensation, upon execution, we issued this individual 10,000 shares of our common stock valued at $50,000 and are obligated to issue him an additional 10,000 shares at such time as additional patents are issued. The recipient was a non-U.S. person and the issuance was exempt from registration under the Securities Act in reliance on an exemption provided by Regulation S promulgated thereunder.

 

On June 1, 2020 we sold a total of 82,818 shares of our common stock for $400,000 to six non-U.S. persons in private transactions. We did not pay a commission or finder’s fee and are using proceeds for working capital. The issuances were exempt from registration under the Securities Act in reliance on an exemption provided by Regulation S promulgated thereunder.

 

On June 4, 2020 we sold 165,632 shares of our common stock for $800,000 to a non-U.S. person in a private transaction. We did not pay a commission or finder’s fee and are using the proceeds for working capital and reducing debt. The issuances were exempt from registration under the Securities Act in reliance on an exemption provided by Regulation S promulgated thereunder.

 

NOTE 4 – RELATED PARTY TRANSACTIONS

 

Early in the first half of 2020 the Company borrowed an additional $2,500 from Xten Capital Group Inc. (“Xten”), a common control entity. On June 24, 2020 the Company paid $250,000 to reduce the debt to Xten. The balance outstanding at June 30, 2020 due Xten is $455,544. The loan is unsecured, noninterest bearing and due on demand.

 

We maintain our corporate offices at 5550 Nicollet Avenue, Minneapolis, MN 55419. We lease the premises from 5550 Nicollet, LLC, a company owned by Mr. Chong. In December 2019 we entered into a month-to-month lease that began January 1, 2020 with a monthly rental rate of $775. We have rented the space continuously through the first six months of 2020. As of June 30, 2020, there is no outstanding balance for rent due to 5550 Nicollet LLC.

 

In the first half of 2020, pursuant to a verbal agreement, Xten provided research and development related expertise and services specific to HNB technologies, devices and intellectual property. Xten billed the Company $270,246 in research and development costs resulting from these activities during the first half of 2020. As of June 30, 2020, we have an accounts payable amount owing to Xten of $59,301 for these services.

 

9

 

 

NOTE 5 – NOTE PAYABLE

 

On May 20, 2013 the Company issued a $50,000 note to an unrelated third party. On March 6, 2020, this note and accrued unpaid interest, upon agreement by the noteholder, were fully satisfied through the conversion of the principal and accrued interest totaling $76,917 into 15,384 common shares of our stock at a rate of $5.00 per share. No gain or loss was recognized from the conversion of this note to the Company’s common stock.

 

NOTE 6 – CONVERTIBLE NOTE

 

On July 14, 2014 the Company issued a $40,000 convertible note to an unrelated third party that was originally issued July 14, 2014 as part of the acquisition of VapAria Solutions. This convertible note matured on December 31, 2019. In February 10, 2020 we fully satisfied any and all obligations of the convertible note through repayment of the principal and accrued interest of $62,323.

 

NOTE 7 – COMMITMENT AND CONTINGENCIES

 

Relating to the December 2013 License Agreement with Xten, a common control entity, beginning in the calendar year in which the first licensed products or licensed services takes place, but not prior to January 1, 2015, the Company is required to pay to Xten, a 3% royalty for revenues with a $50,000 annual minimum royalty commitment.

 

The December 31, 2013 License Agreement with Xten also requires us to pay for the costs associated with maintaining the patent applications and patents licensed to us. For the six months ended June 30, 2020 the Company paid $2,338 in legal fees versus the first six months of 2019 where Xten did not report that it incurred any costs associated with this December 2013 License Agreement.

 

Note 8 – SUBSEQUENT EVENTS

 

On June 17, 2020 the Company entered into a Stock Purchase Agreement with an unrelated stockholder pursuant to which it agreed to repurchase 21,430 shares of its common stock from the stockholder for $2,500. The Stock Purchase Agreement contained customary terms, including cross general releases. On August 10, 2020 the transaction closed. Following the closing of the transaction, the shares have been cancelled and returned to the status of authorized but unissued shares of common stock.

 

On July 17, 2020 we entered into a consulting engagement memorandum with an unrelated third party for the consultant’s guidance and expertise in identifying business opportunities, partners and other skilled consultants in the People’s Republic of China and/or other territories of Asia. As compensation for the services we issued this individual 12,423 shares of our common stock valued at $60,003. The recipient was a non-U.S. person and the issuance was exempt from registration under the Securities Act in reliance on an exemption provided by Regulation S promulgated thereunder.

 

On July 17, 2020 we entered into a consulting engagement memorandum with an unrelated third party for the consultant’s guidance and expertise in identifying potential financiers, partners and other skilled consultants in the People’s Republic of China and/or other territories of Asia. As compensation for the services we issued this individual 6,212 shares of our common stock valued at $30,004. The recipient was a non-U.S. person and the issuance was exempt from registration under the Securities Act in reliance on an exemption provided by Regulation S promulgated thereunder.

 

On July 29, 2020 we entered into an Amended and Restated Operating Agreement (the “Operating Agreement”) of Leap Technology LLC (“Leap Technology”) with Zong Group Holdings LLC (“Zong”) and Leap Management LLC (“LM”). Under the terms of the Operating Agreement and the related Contribution Agreement dated July 24, 2020 (the “Contribution Agreement”), the Company acquired a 55% membership interest in Leap Technology in exchange for the contribution of an exclusive, royalty-free license (the “License Agreement”) for the use in the Asia Pacific countries listed in the Contribution Agreement of certain of our intellectual property, patents pending and patents related to our heated tobacco product technology. It is expected that Leap Technology will form additional business entities to commercialize our propriety technology in those Asia Pacific countries which include China, India, Indonesia, Vietnam, the Philippines, Thailand, Malaysia, Singapore and Hong Kong. The goal of the joint venture is the market development of the Company’s intellectual property in the Asia Pacific region together with other initiatives and the formation business relationships with tobacco companies who operate in the Asia Pacific region.

 

Effective August 1, 2020 the Board of Directors approved annual salaries for its: (1) CEO, Alexander Chong, of $98,400 per annum; (2) COO, William Bartkowski, of $81,600 per annum; and (3) CFO, Daniel Markes, of $90,000 per annum.  To date the Company has not entered into any written employment agreements with the officers. These officers also received a biweekly cash payment consistent with their respective annual salary on July 15, 2020 and July 31, 2020 for services provided.

 

10

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion of our financial condition and results of operations for the three and six months ended June 30, 2020 and 2019 should be read in conjunction with the unaudited financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward looking statements as a result of a number of factors, including those set forth under “Cautionary Statements Regarding Forward-Looking Information” appearing earlier in this report, Part I. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2019, and our other filings with the Securities and Exchange Commission. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward looking statements. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward looking statements. Such statements are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this report.

 

Impact of COVID-19 on the Company

 

In the first half of 2020 the effects of the COVID-19 pandemic began to be felt. While the duration and full impact of the pandemic is unknown at this time, we expect that the pandemic will adversely impact CQENS in several ways. Our business model is dependent upon our ability to enter into strategic partnerships in the future, including alliances with consumer product companies, to enhance and accelerate the development and commercialization of our proposed products. We will also be dependent upon third party manufacturers to produce our proposed products, as well as third party marketing and distribution companies. We believe that our business opportunities are international in nature and include potential partnerships in the UK, the EU and Asia, including the People’s Republic of China. The worldwide pandemic caused by COVID-19 could cause these opportunities to be delayed or significantly limited in their scope should the pandemic continue and /or be prolonged into 2021. We also need to raise additional working capital to provide sufficient funding to bring our proposed products to market. The adverse impact of COVID-19 on the capital markets will make it more difficult for small, pre-revenue companies such as ours to access capital. We will continue to assess the impact of the COVID-19 pandemic on our company, however, at this time we are unable to predict all possible impacts on our company, our operations and our prospects.

 

Overview and plan of operations

 

We are a technology company involved in the development of proprietary and patentable methods for heating plant-based consumable formulations leading to the production of aerosols for safe, effective and efficient inhalation of plant constituents. The technology, often called Heat Not Burn (“HNB”) accomplishes this by heating tobacco to produce an aerosol, but without the accompanying constituents of combustion. Our technology differs from other such technologies currently on the market because the CQENS System is a high-temperature, non-combustion system, unlike the low-temp, non-combustion systems available today. Current applications of the technology include tobacco, hemp-CBD and cannabis where non-combusting methods of preparation for inhalation are believed to be safer and more effective.

 

As previously disclosed, on December 31, 2019, we entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Xten, a related party, pursuant to which we acquired certain intellectual property and other assets. Following the closing of the Asset Purchase Agreement, our business and operations are now focused on commercializing the CQENS System, a patent-pending method of inductively heating tobacco and other substances and ingredients that support reduced risk as a reduced risk product (RRP), given that the technology prevents combustion and prevents consumers from inhaling the dangerous byproducts of combustion. We believe that HNB technologies will be of great interest to the international tobacco industry and the growing hemp-CBD cannabis industries. HNBs represent the latest in tobacco and inhalable technologies, and likely to supplant the electronic vapor system (EVS) technologies including e-cigarettes and electronic nicotine delivery systems. We believe HNBs, if properly designed, will avoid many of the issues that have proved troublesome for EVS’ including thermal decomposition, heating irregularities and the formation and presence of high levels of acrolein and formaldehyde. In the fall of 2019 Philip Morris International introduced its HNB product to U.S. markets. This product, which was sold in more than 40 countries before entering U.S. markets, like other HNB technologies, is a device that heats a tobacco stick, rather than burning it, and testing supports claims that the product can potentially reduce the number of noxious chemicals found in cigarette smoke by 95%.

 

The CQENS System is supported by three patent applications, the most recent of these, a Patent Cooperation Treaty (PCT) patent application, was filed by Xten in January 2019. In May 2019 Xten was informed that the International Searching Authority (ISA) had completed its review of the PCT patent application and issued the International Search Report and Written Opinion relative to that application. The ISA found that 34 of the application’s 55 claims were patentable and the remaining 21 would also be patentable if successfully amended. On September 5, 2019, Xten filed a Chapter II Demand and Article 34 Amendments with the International Bureau of the World International Property Office (WIPO) as a part of what we expect will be a successful effort to obtain a favorable opinion for all of its claims. We have succeeded to these rights with our purchase of the Assets as described earlier in this report.

 

11

 

 

On July 24, 2020, we entered into the Operating Agreement of Leap Technology with Zong and LM. Under the terms of the Operating Agreement and the related Contribution Agreement, the Company acquired a 55% membership interest in Leap Technology in exchange for the contribution of an exclusive, royalty-free License Agreement for the use in the Asia Pacific countries listed in the Contribution Agreement of certain of our intellectual property, patents pending and patents related to our heated tobacco product technology. It is expected that Leap Technology will form additional business entities to commercialize our propriety technology in those Asia Pacific countries which include China, India, Indonesia, Vietnam, the Philippines, Thailand, Malaysia, Singapore and Hong Kong. The goal of the joint venture is the market development of the Company’s intellectual property in the Asia Pacific region together with other initiatives and the formation business relationships with tobacco companies who operate in the Asia Pacific region.

 

Under the terms of the Operating Agreement, there will be five managers of the Leap Technology, three of whom will be designated by the Company and two of whom will be designated by Zong. Zong and LM have jointly agreed to raise equity to fund the operations of the expected additional business entities to be formed by Leap Technology as well as using their best efforts to assist the Company in raising capital. In the event Zong and LM jointly fail to undertake their best efforts, as evidenced by failure to fulfill most of their financial obligations under the Operating Agreement, the Company may exercise a right to repurchase from Leap Technology the CQENS IP (as defined under the Operating Agreement) contributed under the Contribution Agreement for a nominal cash amount.

 

In addition to the Leap Technology agreement, which anticipates an Asian market launch for certain embodiments of our technology, we also expect to make progress in launching product embodiments in the EU and in preparing to submit certain product embodiments to the US FDA in order to secure a Premarket Tobacco Product Authorization (“PMTA”). Due to the development of our business plan and operations, we have determined that accelerated research, product development and global launch objectives requires increased time and involvement from our executive officers. These executive officers have agreed to take on their responsibilities with the Company on a full-time basis for cash compensation. Effective August 1, 2020 the Board of Directors approved annual salaries for its: (1) CEO, Alexander Chong, of $98,400 per annum; (2) COO, William Bartkowski, of $81,600 per annum; and (3) CFO, Daniel Markes, of $90,000 per annum.  To date we have not entered into any written employment agreements with the officers. These officers also received a biweekly cash payment consistent with their respective annual salary on July 15, 2020 and July 31, 2020 for services provided.

 

We raised $2,400,000 in capital in the first half of 2020 through the sale of our common stock to non-U.S. Persons in private transactions. We may seek to raise additional capital through future public or private debt or equity offerings of our securities, although we do not have any commitments from any third parties to provide any capital to us. While we believe that the exclusive rights to the proprietary technology on which our business is predicated could provide us with a significant competitive advantage if we can bring one or more products to market, our ability to accomplish that in the near term is dependent on a successful prototype and positive pre-clinical assessments of the prototype. Given the current lack of a public market for our common stock, our status as a pre-clinical stage company and the difficulties small companies experience in accessing the capital markets, we expect to encounter difficulties in pursuing public or private capital raises. We may also seek to minimize our capital needs by securing partnerships or joint ventures with well capitalized companies in the pharmaceutical or OTC consumer products industries. Until such time as we are able to raise all or a portion of the necessary capital, our ability to continue to implement our business plan will be in jeopardy.

 

Going concern

 

For the first six months of 2020 we reported a net loss of $572,271 and net cash used in operations of $385,995 compared to a net loss of $49,448 and net cash used in operations of $35,885 for the first six months of 2019. At June 30, 2020, we had cash on hand of $1,687,887 and an accumulated deficit of $2,874,321. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2019 contains an explanatory paragraph regarding our ability to continue as a going concern based upon our minimal cash and no source of revenues which may not be sufficient to cover our operating costs. These factors, among others, despite the cash and cash equivalent amount on hand at the end of this quarter, raise substantial doubt about our ability to continue as a going concern and pay our obligations as they become due over the next year. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to raise additional capital, develop a source of revenues, report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company.

 

Results of operations

 

We did not generate any revenues from our operations in either the second quarter or first half of 2020 or 2019. Our total operating expenses for the second quarter of 2020 and the six months then ended increased 1,535.6% and 1,162.3% respectively over those reported in the comparable 2019 periods.

 

General and administrative expenses increased 1.0% in the second quarter of 2020 from the comparable period in 2019 but showed an overall increase of 731.7% for the first six months from the same period in 2019 due mainly to the aggregate of $100,000 bonus payments made to the Company’s management and some slight increases in amortization and office expenses.

 

12

 

 

Research and development expenses in the second quarter of 2020 were $139,790 as we work on variant prototypes. Comparatively, we had no research and development expenses in this same period in 2019. For the first six months of 2020 our research and development expenses were $270,246 against no research and development in the first six months of 2019. Professional fees increased 1,242.1% in the second quarter of 2020 compared to the second quarter of 2019. The first six months of 2020 showed an increase in professional fees of 485.5% over the same 2019 timeframe. These increases are attributable to consulting service fees and increased legal costs primarily due to the filing of additional US and international patent applications related to our HNB technology.

 

We expect that our operating expenses will increase as we continue to develop our business and we devote additional resources towards promoting that growth, most notably reflected in anticipated increases in research and development, general overhead, salaries for personnel and technical resources, as well as increased costs associated with our SEC reporting obligations. However, as set forth elsewhere in this report, our ability to continue to develop our business and achieve our operational goals is dependent upon our ability to raise significant additional working capital. As the availability of this capital is unknown, we are unable to quantify at this time the expected increases in operating expenses in future periods.

 

Liquidity and capital resources

 

Liquidity is the ability of a company to generate sufficient cash to satisfy its needs for cash. As of June 30, 2020, we had $1,687,887 in cash and cash equivalents and a working capital surplus of $1,130,305 compared to $1,298 in cash and cash equivalents and a working capital deficit of $856,012 at December 31, 2019. Our current liabilities decreased $243,817 from December 31, 2019, reflecting the retirement of debt and associated interest payable despite a significant increase in our accounts payable and in our accrued expenses. Our source of operating capital in the first half of 2020 came from the sale of 496,898 shares of our commons stock raising $2,400,000 in capital compared to the same period in 2019 where our sole source of operating capital came from additional borrowings from a related party which loaned us an additional $37,000.

 

The ability of the Company to continue as a going concern is dependent upon the Company obtaining adequate capital to fund operating losses until it becomes profitable. As the company is not generating revenues, continued activities and expenditures to bring product(s) to market as soon as we are able is important. Management believes the currently available funding will be insufficient to finance the Company’s operations for a year from the date of these financial statements and to satisfy our obligations as they become due.

 

In February 2020, the $40,000, principal amount, convertible note was fully satisfied through the repayment of both the principal and accrued unpaid interest totaling $62,323. In March 2020, the $50,000, principal amount, note payable was fully satisfied when both the principal and accrued unpaid interest totaling $76,917 were converted into 15,384 shares of our common stock at $5.00 per share. At June 30, 2020 we owe a related party $455,544 which is due on demand.

 

While we raised $2,400,000 from the sale of our securities during the first half of 2020, we still will need to raise $2,000,000 to $3,000,000 in additional capital during the next 12 months. As we do not have any firm commitments for all or any portion of this necessary capital, there are no assurances we will have sufficient funds to fund our operating expenses and continued development of our products and to satisfy our obligations as they become due over the next 12 months. In that event, our ability to continue as a going concern is in jeopardy.

 

Summary of cash flows

 

   June 30, 2020   June 30, 2019 
Net cash (used) in operating activities  $(385,995)  $(35,885)
Net cash provided by financing activities  $2,112,500   $37,000 
Net cash used in investing activities  $(39,916)  $- 

 

Our cash used in operating activities increased 975.6% in the first six months of 2020 compared the first six months of 2019. During these time periods we used the cash primarily to fund our net losses.

 

During the first six months of 2020 net cash provided by financing activities consisted primarily of $2,400,000 raised from the sale of 496,898 shares of our common stock, repayment and satisfaction in full of the convertible note of $40,000, borrowing of $2,500 and repayment of $250,000 of debt to Xten, a common control entity compared to net cash from $37,000 of additional borrowings in the first six months of 2019 from Xten.

 

In the first half of 2020 net cash used in investing activities consisted of the capitalized intellectual property legal services in the amount of $39,916 compared to no cash used in investing activities during this same period in 2019.

 

13

 

 

Critical accounting policies

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. The more critical accounting estimates include estimates related to revenue recognition, accounts receivable allowances and impairment of long-lived assets. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 2 to our audited consolidated financial statements for 2019 appearing in our 2019 10-K.

 

Off balance sheet arrangements

 

As of the date of this report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable for a smaller reporting company.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures.

 

We maintain “disclosure controls and procedures” as such term is defined in Rules 13a-15(e) under the Securities Exchange Act of 1934. In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Based on their evaluation as of the end of the period covered by this report, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were not effective to ensure that the information relating to our company required to be disclosed in our Securities and Exchange Commission reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer, to allow timely decisions regarding required disclosure due to the presence of continuing material weakness in our internal control over financial reporting as reported in our 2019 10-K. These material weaknesses in our internal control over financial reporting result from limited segregation of duties and limited multiple level of review in the financial close process.

 

The existence of the continuing material weaknesses in our internal control over financial reporting increases the risk that a future restatement of our financials is possible. In order to remediate these material weaknesses, we will need to expand our accounting resources. We will continue to monitor and evaluate the effectiveness of our disclosure controls and procedures and our internal control over financial reporting on an ongoing basis, however, we do not expect that the deficiencies in our disclosure controls will be remediated until such time as we have remediated the material weaknesses in our internal control over financial reporting. We had expected to expand our accounting resources in 2018, which was subsequently delayed into 2019 and has now been delayed into 2020. Given the uncertainties with our ability to raise working capital as discussed earlier in this report, there are no assurances we will be able to remediate the material weaknesses in our internal control over financial reporting during 2020.

 

Changes in Internal Control over Financial Reporting.

 

There have been no changes in our internal control over financial reporting during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

14

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

In addition to the other information set forth in this report you should carefully consider the risk factors in Part I, Item 1A in our 2019 10-K and our subsequent filings with the Securities and Exchange Commission, which could materially affect our business, financial condition or future results. These cautionary statements are to be used as a reference in connection with any forward-looking statements, written or oral, which may be made or otherwise addressed in connection with a forward-looking statement or contained in any of our subsequent filings with the Securities and Exchange Commission.

 

Leap Technology is a newly formed entity with no operating history.

 

As disclosed earlier in this report, in July 2020 we became a member of Leap Technology through the contribution of a license for certain of our intellectual property. Leap Technology is a newly formed entity with no operating history and its operations are subject to all the risks inherent in the establishment of a new business enterprise. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays that are frequently encountered in a newly-formed company. There can be no assurance that at this time that Leap Technology will be able to implement its business plan, generate revenues, operate profitably or will have adequate working capital to meet its obligations as they become due. Prospective investors must consider the risks and difficulties frequently encountered by early stage companies, particularly in rapidly evolving markets. We cannot be certain that Leap Technology’s business strategy will be successful or that it will successfully address these risks. In the event that Leap Technology does not successfully address these risks, its business, prospects, financial condition, and results of operations could be materially and adversely affected and it may not have the resources to continue or expand our business operations. In that event, any benefits we expect to receive from Leap Technology would not materialize.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None, except as otherwise previously disclosed, we have not issued any unregistered securities during the period covered by this report.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable to our company’s operations.

 

Item 5. Other Information.

 

On June 17, 2020 the Company entered into a Stock Purchase Agreement with an unrelated stockholder pursuant to which it agreed to repurchased 21,430 shares of its common stock from the stockholder for $2,500. The Stock Purchase Agreement contained customary terms, including cross general releases. On August 10, 2020 the transaction closed. Following the closing of the transaction, the shares have been cancelled and returned to the status of authorized but unissued shares of common stock.

 

15

 

 

Item 6. Exhibits.

 

No.   Exhibit Description   Form  

Date

Filed

  Number   Herewith
2.1   Share Exchange Agreement and Plan of Reorganization dated April 11, 2014 by and between OICco Acquisition IV, Inc., VapAria Corporation and the listed shareholders   8-K   4/11/14   2a    
3.1   Amended and Restated Certificate of Incorporation   S-1   6/30/10   3.C    
3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation   8-K   8/21/14   3.4    
3.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation   10-Q   11/19/16   3.5    
3.4   Bylaws   S-1   3/29/10   3(b)    
10.1   Form of Stock Purchase Agreement   8-K   6/5/20   10.1    
10.2   Form of Amended and Restated Operating Agreement dated July 24, 2020 of Leap Technology LLC (“Leap Technology”) by and between CQENS Technologies Inc., Zong Group Holdings LLC and Leap Management LLC.   8-K   7/29/20   10.1    
10.3   Form of Contribution Agreement Via Exclusive Licensing Agreement dated July 24, 2020 by and between CQENS Technologies Inc. and Leap Technology LLP   8-K   7/29/20   10.2    
10.4   Form of Intellectual Property License Agreement dated July 24, 2020 by and between CQENS Technologies Inc. and Leap Technology LLP   8-K   7/29/20   10.3    
31.1   Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer               Filed
31.2   Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer and Chief Financial Officer               Filed

32.1

 

Section 1350 Certification

              Filed
101.INS   XBRL Instance Document               Filed
101.SCH   XBRL Taxonomy Extension Schema Document               Filed
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document               Filed
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document               Filed
101.LAB   XBRL Taxonomy Extension Label Linkbase Document               Filed
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document               Filed

 

16

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CQENS Technologies Inc.
   
August 14, 2020 By: /s/ Alexander Chong
    Alexander Chong, Chief Executive Officer
     
August 14, 2020 By: /s/ Daniel Markes
    Daniel Markes, Chief Financial Officer

 

17